DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION	
4040 North Central Expressway, Suite 3	00 1/13/2020-1/24/2020*	
Dallas, TX 75204	FEI NUMBER	
(214)253-5200 Fax: (214)253-5314	3004549371	
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED		
Larry D. Brim, II, DPh, Pharmacist-in-	Charge/Co-Owner	
FIRM NAME	STREET ADDRESS	
Claremore Compounding Center, Inc.	1151 N. Lynn Riggs Blvd	
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED	
Claremore, OK 74017-3068	Producer of non-sterile drug products	
observations, and do not represent a final Agency determination observation, or have implemented, or plan to implement, correct action with the FDA representative(s) during the inspection or st	ive(s) during the inspection of your facility. They are inspectional a regarding your compliance. If you have an objection regarding an ative action in response to an observation, you may discuss the objection or submit this information to FDA at the address above. If you have any s above.	
questions, please contact FDA at the phone number and address		

Specifically, your firm is using orange food color that is non-pharmaceutical grade to make drug products. Examples include lot #95806 of hydrocodone/dextromethorphan 10mg/10mg capsules made on 12/10/19 and lot #94010 of hydrocodone/dextromethorphan 5mg/5mg capsules made on 9/11/19.

OBSERVATION 2

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, your firm does not have a written stability testing program to determine Beyond Use Dates (BUD)/expiration dates placed on all your drug products. For example,

- a) Lot #95371 of Dry Skin Moisturizing (OTC) 5% 1% Cream (containing ^{(b) (4)} and hydrocortisone) made on 11/20/19 was assigned a BUD of 360 days.
- b) Lot #94404 of CCC Cold Max 100-5-10-2mg per 5mL suspension (containing guaifenesin, phenylephrine HCI, chlorpheniramine Maleate and dextromethorphan hydrobromide) made on 10/1/19 was assigned a BUD of 180 days.
- c) Lot #94402 of CCC Coughist PE 100-5-2mg per 5mL suspension (containing guaifenesin, phenylephrine HCI, and chlorpheniramine maleate) made on 10/1/19 was assigned a BUD of 180 days.
- d) Jungle Juice Liquid (containing (b) (4) and lidocaine): Lot #92698 made on 7/9/19, lot #93496 made on 8/16/19, and lot #94749 made on 10/17/19 were each assigned a BUD of 360 days.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Margaret M Annes, CSO		Margaret M Annes CSO Stoped by Margaret M. Annes -S Dale Signed 01-24-2020 08 04 50	DATE ISSUED 1/24/2020
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATION	ONS	PAGE 1 of 3 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION							
Dallas, TX 75	ntral Expressway, Suite 300	DATE(S) OF INSPECTION 1/13/2020-1/24/202 FEI NUMBER 3004549371	20*				
NAME AND TITLE OF INDIVIDUAL	то wном report issued , II, DPh, Pharmacist-in-Cha	rgo/Co-Ounor					
FIRM NAME	, II, DPN, PNARMACISt-IN-CNA	STREET ADDRESS					
	pounding Center, Inc.	1151 N. Lynn Riggs Blvd					
CITY, STATE, ZIP CODE, COUNT Claremore, OK		TYPE ESTABLISHMENT INSPECTED Producer of non-sterile drug products					
7/5/19 ar f) Psoria-S hydrocor	 e) Jungle Ointment (containing (b) (4) hydrocortisone and lidocaine): Lot #92655 made on 7/5/19 and lot #92915 made on 7/19/19 were each assigned a BUD of 360 days. f) Psoria-Stop (Coal Tar/HC) OTC 5%-1% Ointment (containing coal tar topical solution and hydrocortisone): Lot #92724 made on 7/10/19 and lot #94694 made on 10/15/19 were each assigned a BUD of 180 days. 						
Testing and rele	OBSERVATION 3 Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.						
	our firm does not conduct rou our firm. Examples include the f		all drug products				
 a) Lot #95371 of Dry Skin Moisturizing (OTC) 5% - 1% Cream (containing ^{(b) (4)} and hydrocortisone) made on 11/20/19. b) Lot #94404 of CCC Cold Max 100-5-10-2mg per 5mL suspension (containing guaifenesin, phenylephrine HCI, chlorpheniramine Maleate and dextromethorphan hydrobromide) made on 10/1/19. c) Lot #94402 of CCC Coughist PE 100-5-2mg per 5mL suspension (containing guaifenesin, phenylephrine HCI, and chlorpheniramine maleate) made on 10/1/19. d) Jungle Juice Liquid (containing (b) (4) and lidocaine): Lot #92698 made on 7/9/19, lot #93496 made on 8/16/19, and lot #94749 made on 10/17/19. e) Jungle Ointment (containing (b) (4) hydrocortisone and lidocaine): Lot #92655 made on 7/5/19 and lot #92915 made on 7/19/19. f) Psoria-Stop (Coal Tar/HC) OTC 5%-1% Ointment (containing coal tar topical solution and hydrocortisone): Lot #92724 made on 7/10/19 and lot #94694 made on 10/15/19. 							
*DATES OF INSPECTION							
SEE REVERSE OF THIS PAGE	employee(s) signature Margaret M Annes, CSO	Margaret M Annes CSO Signed By Margaret M. A Date Signed 01-24-20201	DATE ISSUED 1/24/2020				
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INS	SPECTIONAL OBSERVATIONS	PAGE 2 of 3 PAGES				

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
4040 North Ce			DATE(S) OF INSPECTION 1/13/2020-1/24/2020*		
Dallas, TX 75	5204		FEINUMBER 3004549371		
(214) 253-5200) Fax:(214)253-5314		00010100/1		
NAME AND TITLE OF INDIVIDUA					
Larry D. Brin	n, II, DPh, Pharmacist-in-	-Charge/Co-Ow street address			
100000000000000000000000000000000000000	ompounding Center, Inc. 1151 N. Lynn Riggs Blvd				
Claremore, OF		22/22/12/2010/2010/2010/2010/2010/2010/	TYPE ESTABLISHMENT INSPECTED Producer of non-sterile drug products		
1/13/2020(Mon)), 1/14/2020(Tue), 1/15/2020(W	/ed), 1/16/2020	(Thu), 1/17/2020(Fri), 1/24	l/2020(Fri)	
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Margaret M Annes, CSO		Margaret M Annes CSU and By Margaret M. Annes - State Signed 01-24-2020 08 04 S Date Signed 01-24-2020 08 04 S	DATE ISSUED 1/24/2020	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL O	OBSERVATIONS	PAGE 3 of 3 PAGES	